Showing results (211-220 of 617) with videos related to

Sort By:
Pageof 62
Leukemia|March 28, 2024
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patientsShai Shimony, Jacqueline S Garcia, Julia Keating, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 10, 2019
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation SyndromePeter Valent, Cem Akin, Patrizia Bonadonna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2019
MARS: Mutation-Adjusted Risk Score for Advanced Systemic MastocytosisMohamad Jawhar, Juliana Schwaab, Iván Álvarez-Twose, et al.
Blood|April 21, 2009
Identification of AML1-ETO modulators by chemical genomicsSteven M Corsello, Giovanni Roti, Kenneth N Ross, et al.
Annals of Hematology|March 26, 2013
Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II studyKirsten Merx, Alice Fabarius, Philipp Erben, et al.
The Journal of Clinical Investigation|September 7, 2016
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemiaPatrick D Bhola, Brenton G Mar, R Coleman Lindsley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host diseaseDaniel J DeAngelo, Ephraim P Hochberg, Edwin P Alyea, et al.
Leukemia Research|May 18, 2021
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)Fiona Taylor, Xiaoran Li, Christine Yip, et al.
Journal of Neuropathology and Experimental Neurology|July 31, 2018
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral EdemaMatthew Torre, Isaac H Solomon, Claire L Sutherland, et al.
Leukemia & Lymphoma|June 17, 2020
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Asiri Ediriwickrema, Ritika Dutta, et al.
Pageof 62